Comparison
Bremelanotide vs. SNAP-8
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Cosmetic
CAS no.
189691-06-3
868844-74-0
Molecular weight
1025.18 g/mol
1075.16 g/mol
Half-life
2.7 h
no data
Sequence
Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OHAc-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2Mechanism of action
Bremelanotide
Bremelanotide is a cyclic peptide that binds non-selectively to melanocortin receptors (MC1R through MC5R) — with highest affinity at MC4R in the central nervous system. The precise role of MC4R activation in sexual behaviour is not fully understood; animal data show effects on hypothalamic circuits. Peripheral effects (blood pressure, hyperpigmentation) are attributed to MC1R/MC2R.
SNAP-8
SNAP-8 is an octapeptide variant of Argireline. The sequence corresponds to the N-terminus of the SNAP-25 protein. As with Argireline, the postulated mechanism is competitive inhibition of the SNARE complex needed for acetylcholine vesicle fusion at the neuromuscular endplate. According to the manufacturer the two extra C-terminal amino acids increase SNARE-complex affinity — there are individual industry studies on this but no independent systematic confirmation.
Evidence base
Highest evidence
Human RCT
Human trial
Studies
5
3
of which in humans
5
1
Effects recorded
3
3
Open conflicts
0
0
Documented adverse events
2
1